Ventracor chalks up first revenues

By Ruth Beran
Tuesday, 20 September, 2005

Ventracor (ASX:VCR) has received its first revenues, in the form of a cheque from the University of Maryland Medical Centre as payment for a VentrAssist left ventricular assist device (LVAD) recently implanted in a patient as part of its US clinical trial.

The company previously indicated it would reach the milestone before the end of 2005.

Personalised melanoma vaccine cuts risk of recurrence

Adding a personalised, mRNA-based cancer vaccine to standard immunotherapy after surgery for...

Research project to produce fish-free omega-3

SCU researchers are investigating how to grow omega-3-producing microorganisms more cheaply...

Biodegradable smart patch can detect and treat blood clots

Researchers have developed a biodegradable smart patch that detects pressure changes and releases...

Content from other channels on our network

Optimising connectivity: Peninsula University Hospital

When pressure narrows the choices healthcare leaders can see

When AI Wastes More Than a Patient's Time

Aged care's Single Assessment System has "undermined public confidence", ombudsman finds

53.6% increase on practitioners referred to a tribunal, Ahpra annual report reveals

MathWorks certified to provide guidance for AI‍-‍assisted engineering

NSW opens expressions of interest for Bradfield enterprise precinct

UQ researchers develop faster membrane technology

Rockwell Automation introduces SecureOT capabilities for OEMs

METTLER TOLEDO's IND700 and ProWorks Studio bring adaptable weighing control to production facilities

Six on the shelf: diverse new food products in November

tna's food packaging solution wins gold at the Good Design Awards 2026

NSW Wine Recovery Program now open for applications

AIP to host its final State of Industry Webinar for 2026

The cost of Cyclospora outbreaks in the states